Zanubrutinib Monotherapy for Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pooled Analysis of Three Studies.


Journal

Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864

Informations de publication

Date de publication:
09 2022
Historique:
received: 23 05 2022
accepted: 20 06 2022
pubmed: 29 7 2022
medline: 27 8 2022
entrez: 28 7 2022
Statut: ppublish

Résumé

Zanubrutinib is a highly selective irreversible inhibitor of Bruton tyrosine kinase which has shown significant activity in lymphoid malignancies in early phase studies. We report here the long-term follow-up outcomes of zanubrutinib in various lines of therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). This post hoc analysis pooled patients with treatment-naïve (TN) or relapsed/refractory (R/R) CLL/SLL receiving zanubrutinib monotherapy from three phase 1/2 studies (BGB-3111-1002, BGB-3111-AU-003, BGB-3111-205). A total of 211 patients with CLL/SLL (TN 19, R/R 192) were included. After weighting (TN 19, R/R 24), the overall response rate (ORR) was 95.4% and significantly higher in the TN group than in the R/R group (100 vs. 91.0%, p < 0.0001). ORR was also significantly higher in the TN group than in the one prior line of therapy group (100 vs. 98.9%, p < 0.0001). Among those with R/R disease, the ORR was 97.8% in patients with one prior line of therapy (n = 79) and 90.7% in those with > 1 prior lines of therapy (n = 85; p = 0.080). The median follow-up times were 50.1, 35.7, and 45.9 months for TN, R/R and all cohorts, respectively. Progression-free survival and overall survival were significantly longer in the TN group and only one prior line of therapy group compared with the > 1 prior lines of therapy group (all p < 0.05) and were similar in the TN group compared with the one prior line therapy group. Efficacy was similar regardless of the presence of genomic aberrations. Most frequent grade ≥ 3 adverse events were infections (41.7%), neutropenia (34.1%), and thrombocytopenia (9.4%). Atrial fibrillation occurred in only 1.9% of patients. With extended follow-up, zanubrutinib yielded long-term benefits and demonstrated a favorable safety profile for patients with TN or RR CLL/SLL. Earlier utilization of zanubrutinib was associated with better outcomes. Clinical Trials.gov identifiers, NCT03189524, NCT02343120 (retrospectively registered), and NCT03206918 (retrospectively registered).

Identifiants

pubmed: 35900694
doi: 10.1007/s12325-022-02238-7
pii: 10.1007/s12325-022-02238-7
doi:

Substances chimiques

Piperidines 0
Pyrazoles 0
Pyrimidines 0
zanubrutinib AG9MHG098Z

Banques de données

ClinicalTrials.gov
['NCT03189524', 'NCT03206918', 'NCT02343120']

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't

Langues

eng

Pagination

4250-4265

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature.

Références

Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2011;118:4313–20.
doi: 10.1182/blood-2011-06-338855
Niemann CU, Wiestner A. B-cell receptor signaling as a driver of lymphoma development and evolution. Semin Cancer Biol. 2013;23:410–21.
doi: 10.1016/j.semcancer.2013.09.001
Herman SE, Mustafa RZ, Gyamfi JA, et al. Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. Blood. 2014;123:3286–95.
doi: 10.1182/blood-2014-02-548610
Ponader S, Chen SS, Buggy JJ, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119:1182–9.
doi: 10.1182/blood-2011-10-386417
de Rooij MF, Kuil A, Geest CR, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood. 2012;119:2590–4.
doi: 10.1182/blood-2011-11-390989
Ponader S, Burger JA. Bruton’s tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies. J Clin Oncol. 2014;32:1830–9.
doi: 10.1200/JCO.2013.53.1046
Hillmen P, Eichhorst B, Brown J, et al., editors. First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. In: Proceedings of the 2021 European hematology association virtual congress; 2021.
NMPA. Zanubrutinib Label in CDE (CXHS2000037). https://www.cde.org.cn/main/xxgk/postmarketpage?acceptidCODE=5b25b17659c2ce6026869f57909e2053 .
Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107:13075–80.
doi: 10.1073/pnas.1004594107
Tam CS, Trotman J. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019;134:851–9.
doi: 10.1182/blood.2019001160
Xu W, Yang S, Zhou K, et al. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study. J Hematol Oncol. 2020;13:48.
doi: 10.1186/s13045-020-00884-4
Zhu J, Li J, Zhou J, et al. BGB-3111, a highly specific BTK inhibitor, is well tolerated and highly active in Chinese patients with relapsed/refractory B-cell malignancies: initial report of a phase 1 trial in China. Washington DC: American Society of Hematology; 2017.
Ou YC, Tang Z, Novotny W, et al. Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma. Leuk Lymphoma. 2021;62:2612–24.
doi: 10.1080/10428194.2021.1929961
Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–56.
doi: 10.1182/blood-2007-06-093906
Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–68.
doi: 10.1200/JCO.2013.54.8800
Yang D, Dalton JE, editors. A unified approach to measuring the effect size between two groups using SAS
Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009;38:1228–34.
doi: 10.1080/03610910902859574
Zhou K, Zou D, Zhou J, et al. Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials. J Hematol Oncol. 2021;14:167.
doi: 10.1186/s13045-021-01174-3
Ahn IE, Tian X. Prediction of outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: development and validation of a four-factor prognostic model. J Clin Oncol. 2021;39:576–85.
doi: 10.1200/JCO.20.00979
O’Brien SM, Byrd JC, Hillmen P, et al. Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. Am J Hematol. 2019;94:554–62.
doi: 10.1002/ajh.25436
Nadeu F, Delgado J, Royo C, et al. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Blood. 2016;127:2122–30.
doi: 10.1182/blood-2015-07-659144
Ahn IE, Farooqui MZH, Tian X, et al. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. Blood. 2018;131:2357–66.
doi: 10.1182/blood-2017-12-820910
O’Brien S, Furman RR, Coutre S, et al. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018;131:1910–9.
doi: 10.1182/blood-2017-10-810044
Stephens DM, Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood. 2019;133:1298–307.
doi: 10.1182/blood-2018-11-846808
Tam CS, Opat S, D’Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood. 2020;136:2038–50.
doi: 10.1182/blood.2020006844
Byrd JC, Hillmen P. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39:3441–52.
doi: 10.1200/JCO.21.01210

Auteurs

Wei Xu (W)

Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, Jiangsu, China. xuwei10000@hotmail.com.

Shenmiao Yang (S)

Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.

Constantine S Tam (CS)

Peter MacCallum Cancer Centre, Royal Melbourne Hospital, Melbourne, VIC, Australia.
University of Melbourne, Parkville, VIC, Australia.
St Vincent's Hospital, Fitzroy, VIC, Australia.
Victorian Comprehensive Cancer Centre, Melbourne, VIC, Australia.

John F Seymour (JF)

Peter MacCallum Cancer Centre, Royal Melbourne Hospital, Melbourne, VIC, Australia.
University of Melbourne, Parkville, VIC, Australia.
Victorian Comprehensive Cancer Centre, Melbourne, VIC, Australia.

Keshu Zhou (K)

Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.

Stephen Opat (S)

Monash Health, Monash University, Clayton, VIC, Australia.

Lugui Qiu (L)

Institute of Hematology, Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.

Mingyuan Sun (M)

Institute of Hematology, Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.

Tingyu Wang (T)

Institute of Hematology, Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.

Judith Trotman (J)

Concord Repatriation General Hospital, Concord, NSW, Australia.
University of Sydney, Concord, NSW, Australia.

Ling Pan (L)

West China Hospital of Sichuan University, Chengdu, China.

Sujun Gao (S)

The First Hospital of Jilin University, Changchun, China.

Jianfeng Zhou (J)

Tongji Hospital, Tongji Medical College, Wuhan, China.

Daobin Zhou (D)

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.

Jun Zhu (J)

Peking University Cancer Hospital, Institute (Beijing Cancer Hospital), Beijing, China.

Yuqin Song (Y)

Peking University Cancer Hospital, Institute (Beijing Cancer Hospital), Beijing, China.

Jianda Hu (J)

Fujian Medical University Union Hospital, Fuzhou, China.

Ru Feng (R)

Nanfang Hospital of Southern Medical University, Guangzhou, China.

Haiwen Huang (H)

The First Hospital of Soochow University, Suzhou, China.

Dan Su (D)

BeiGene (Beijing) Co., Ltd., Beijing, China.

Miao Shi (M)

BeiGene (Beijing) Co., Ltd., Beijing, China.

Jianyong Li (J)

Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, Jiangsu, China. lijianyonglm@126.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH